Risks
4 risks
Risk Intelligence
Regulatory delays at Malaysia facility
View Risks →Biocon Limited — Q2 FY24
Biocon's Q2 FY24 consolidated revenue from operations grew 49% YoY to INR 3,462 crore, driven by biosimilars revenue nearly doubling post-Viatris acquisition.
neutral
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Biocon's Q2 FY24 consolidated revenue from operations grew 49% YoY to INR 3,462 crore, driven by biosimilars revenue nearly doubling post-Viatris acquisition. Core EBITDA rose 35% to INR 1,100 crore with a 32% margin, but reported PAT fell to INR 126 crore due to higher depreciation and interest costs. Biosimilar market share gains in the US (Fulphila 19%, Ogivri 12%, insulin glargine 11%) were offset by slower-than-expected adalimumab uptake and a CRL for insulin aspart. Management guided for Biocon Biologics to achieve $1 billion revenue for FY24, mid-teen constant currency growth in Syngene, and improved H2 performance in generics. Key risks include regulatory delays at the Malaysia facility and pricing pressure in the US biosimilar market.
बायोकॉन की दूसरी तिमाही (Q2) में कुल कमाई पिछले साल से 49% बढ़कर 3,462 करोड़ रुपये हो गई। इसकी मुख्य वजह बायोसिमिलर (महंगी दवाओं के सस्ते विकल्प) की बिक्री में दोगुनी बढ़ोतरी है, जो विआट्रिस कंपनी को खरीदने के बाद हुई। कंपनी की मुख्य कमाई (EBITDA) 35% बढ़कर 1,100 करोड़ रुपये रही, लेकिन मुनाफा (PAT) सिर्फ 126 करोड़ रुपये रहा, क्योंकि पुरानी मशीनों की घिसाई और कर्ज के ब्याज का खर्च बढ़ गया। अमेरिका में बायोसिमिलर दवाओं (जैसे फुलफिला, ओगिवरी, इंसुलिन) की बिक्री बढ़ी, लेकिन कुछ नई दवाओं की बिक्री उम्मीद से कम रही। कंपनी को उम्मीद है कि इस साल बायोकॉन बायोलॉजिक्स 1 अरब डॉलर की कमाई करेगी। मुख्य जोखिम हैं—मलेशिया फैक्ट्री में देरी और अमेरिका में दवाओं की कीमतों पर दबाव।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Fulphila US market share
19%
+8pp YoY
Biosimilar pegfilgrastim market share grew from 11% in September last year.
Ogivri US market share
12%
+2pp YoY
Biosimilar trastuzumab market share increased from 10% last year.
Insulin glargine US market share
11%
flat YoY
Market share held steady; additional volume from closed-door networks not captured in IQVIA.
Hulio market share in Germany
18%
flat YoY
Biosimilar adalimumab maintained share in Germany; US adoption slower than expected.
What Changed vs Last Quarter
NEW
Biocon Biologics to deliver $1 billion revenue in FY24
Management reaffirmed full-year revenue guidance of $1 billion for Biocon Biologics, driven by market share gains and new product launches.
NEW
Generics H2 performance to improve over H1
Generics business expects improved second half performance, with formulations steady at ~INR 400 crore per half and API recovery, but full-year growth revised to low teens/high single digit.
NEW
Ustekinumab filing on track by end of 2023
Biocon Biologics remains on track to file ustekinumab (Stelara biosimilar) before the end of 2023, with denosumab filing expected by end of next year.
UPDATED
Syngene mid-teen constant currency growth for FY24
Syngene is expected to deliver mid-teen constant currency growth for the full year, supported by strong performance in development and manufacturing services.
DROPPED
Biosimilars core EBITDA margins to return to mid-thirties by end of FY24
Management expects core EBITDA margins for Biocon Biologics to recover to mid-thirties as legacy rebate issues normalize and integration completes.
DROPPED
Generics high double-digit CAGR over 5 years
Generics business expected to grow at 17-20% CAGR over the next 4-5 years, driven by peptides, injectables, and fermentation.
DROPPED
Biocon Biologics CapEx of $150 million for FY24
Capital expenditure for biosimilars business guided at $150 million, primarily for Malaysia expansion and insulin capacity ramp-up.
NEW RISK
Regulatory delays at Malaysia facility
FDA issued a CRL for insulin aspart due to pre-approval inspection deficiencies at the Malaysia facility; resolution timeline uncertain.
NEW RISK
Pricing pressure in generics API business
API business faced pricing pressure and muted offtake due to customer inventory stocking; recovery expected but uncertain.
RISK GONE
Regulatory delays for insulin aspart and bevacizumab approvals
USFDA inspections at Malaysia facility resulted in observations; CAPA plans submitted but approval timelines for insulin aspart and bevacizumab remain uncertain.
RISK GONE
Pricing pressure and rebate volatility in U.S. biosimilars
Legacy rebate contracts caused a $15 million one-off impact on pegfilgrastim; pricing dynamics vary by product and channel, and further rebate adjustments could affect margins.
Fast read
Guidance and risk preview
Management reaffirmed full-year revenue guidance of $1 billion for Biocon Biologics, driven by market share gains and new product launches.
FDA issued a CRL for insulin aspart due to pre-approval inspection deficiencies at the Malaysia facility; resolution timeline uncertain.
View Risks →